Sharekhan

Data is delayed. Analysis is best done in real-time! Open a FREE Sharekhan Demat A/c in 15 mins* and continue your analysis with real-time data.

Market Data

Essential tool: analyze, trade, manage, decide.

What’s Your Call?

Collective community sentiment on Unjha Formulations Ltd

Your Vote -

Buy

50.00%

Hold

0.00%

Sell

50.00%

50.00%

2 users have voted

No Records Found

Option Chain

Analyzes market sentiment, predicts Unjha Formulations Ltd' movement.

NO_RECORD_FOUND

News

Media spotlight triggers stock stock attention, sentiment.

  • Unjha Formulatio - Publish Audited Financial Results For The Quarter And Year Ended As On 31/03/2026

    20 May 2026, 3:36PM Regulation 33(3) of SEBI (lodr) 2015
  • Unjha Formulatio - Publish Audited Financial Results For The Quarter And Year Ended As On 31/03/2026

    20 May 2026, 3:34PM Regulation 33(3) of SEBI (lodr) 2015
  • Unjha Formulatio posts Q4 net loss of Rs 0.74 cr

    18 May 2026, 2:40PM The company reported standalone net loss during the quarter stood at Rs 0.74 crore as compared to net loss of Rs 0.41 crore in the previous year quart
  • Unjha Formulatio - INTEGRATED FILING(FIN) FOR THE QUARTER AND YEAR ENDED 31/03/2026

    18 May 2026, 2:36PM INTEGRATED FILING
  • Unjha Formulatio - Board Meeting Outcome for APPROVAL OF AUDITED FR FOR QUARTER AND YEAR ENDED AS ON 31.03.2026

    18 May 2026, 2:18PM REGULATION 33 OF SEBI LODR 2015
  • Unjha Formulatio - Declaration With Respect To Non-Applicability Of Large Corporate Framework Pursuant To SEBI Circular No. S

    7 May 2026, 2:22PM Declaration with respect to non-applicability of large corporate vide SEBI circular Dated 26.11.2018
  • Unjha Formulatio - Declaration With Respect To Non-Applicability Of Large Corporate Framework Pursuant To SEBI Circular No. S

    7 May 2026, 2:21PM Declaration with respect to non-applicability of large corporate vide SEBI circular Dated 26.11.2018
  • Unjha Formulatio - Board Meeting Intimation for Board Meeting - Date: 18.05.2026 (AUDITED FINANCIAL RESULTS AS ON 31/03/2026)

    22 Apr 2026, 2:55PM Unjha Formulations Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 18/05/2026 ,inter alia, to consider a
  • Unjha Formulatio has submitted to BSE the Shareholding Pattern for the Period Ended March 31, 2026

    10 Apr 2026, 3:21PM As of March 2026, 36.92% is owned by Indian Promoters and 63.08% by Public. <p align=justify> Top four Promoters holding highest number of shares of U
  • Unjha Formulatio - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018

    10 Apr 2026, 2:54PM Regulation 74(5) of SEBI (DP) Regulation

Key fundamentals

Evaluate the intrinsic value of Unjha Formulations Ltd stock 

Name March-26 March-25 March-24 March-23 March-22
Assets 3.8434 3.1387 2.7312 2.4534 2.1708
Liabilities 3.8434 3.1387 2.7312 2.4534 2.1708
Equity 4.4805 4.4805 4.4805 4.4805 4.4805
Gross Profit 1.1036 0.5154 0.5758 0.4332 0.3217
Net Profit 0.7047 0.4075 0.2779 0.2824 0.2524
Cash From Operating Activities 1.2438 -0.0449 1.0261 -0.3146 0.2765
NPM(%) 4.47 2.93 1.5 2.14 1.78
Revenue 15.7487 13.8621 18.496 13.1537 14.1639
Expenses 14.6451 13.3467 17.9202 12.7205 13.8422
ROE(%) 15.36 8.88 6.05 6.15 5.5

Shareholding Pattern

Corporate Action

XD-Date Dividend-Amount Dividend-% Dividend Yield(%GE) Price on that day

Peers

Other companies within the same industry or sector that are comparable to Unjha Formulations Ltd

Company Price Price (% change) pe(x) EV/EBITDA(x) ROE(%) ROCE(%)
Albert David Ltd 702.35 -0.59 0.00 11.03 -26.19 0.71
Lotus Eye Hospital and Institute Ltd 107.05 1.28 352.23 40.20 3.55 0.00
Bharat Immunological and Biologicals Corporation Ltd 17.55 0.29 0.00 83.47 -39.50 0.00
Astec Lifesciences Ltd 768.00 4.22 0.00 37.91 -363.15 0.00

Company Info

M/s. Unjha Formulations Limited was established in June 1987 as a partnership firm for manufacturing Pharmaceutical Formulations at Khali Char Rasta, Tal: Sidhpur, Dist: Mehsana. The firm has now been converted into a Public Limited Company vide Certificate of Incorporation No.04/22932 of 1994-95 dated 2.9.94. The company is presently manufacturing pharmaceutical formulations like liquids, powder, tablets, capsules, injectibles etc. The Company is one of the largest manufacturers of Isabgul products in India. The company is located in the heart of Isabgul growing region, worldwide. The Company has seen uninterrupted growth since incorporation and the sales have consistently risen from Rs.85 lacs in 1991-92 to Rs.348.50 lacs in 1994-95. The Company is presently manufacturing an extensive range of Pharmaceutical Formulations for human consumption and for veteniary use. The sales therefore are divided into the two segments viz: human consumption and veterinary products. In the proposed expansion programme, the company proposes to manufacture additional tablets and injectibles for human consumption and also catering veterinary market. The company has identified the market segment for veterinary drugs as a less competitive market. Other Companies promoted by the promoter are in the business of procuring and trading in Psyllium husk. The Company procures this processed husk for its various products. Therefore, there is no conflict of interest. Also not all the raw material is procured from companies promoted by the same promoters and procurement is based on best rates available. "Gelax" is one of the main products of the company, catering to the domestic market. The Company has signed a MOU with the Indian Immunological Hyderabad (a unit of the National Dairy Development Board) for the offtake of their products. The Company has seen its exports continuously increase from Rs.5.52 lacs in 1991-92 to Rs.38.56 lacs in 1994-95. The company has received Export Orders from Companies in Kenya, and Dubai for Magnesium Silicate Compound and Isabgul Products, worth Rs.46.10 lacs. The Company is operating in an industry where there are major pharmaceutical companies - both Indian and Multinational - operating. However the company has an inherent advantage in that it is located in the heart of the Isabgul growing regions in the world with promoters well experienced in the procurement of Psyllium Husk - the major raw material for the company's products. Also it has firm marketing tie up with a major concern which has a strong brand image. 2007 E-mail ID for Investor Complaints :unjfor@sancharnet.in

M/s. Unjha Formulations Limited was established in June 1987 as a partnership firm for manufacturing Pharmaceutical Formulations at Khali Char Rasta, Tal: Sidhpur, Dist: Mehsana. The firm has now been converted into a Public Limited Company vide Certificate of Incorporation No.04/22932 of 1994-95 dated 2.9.94. The company is presently manufacturing pharmaceutical formulations like liquids, powder, tablets, capsules, injectibles etc. The Company is one of the largest manufacturers of Isabgul products in India. The company is located in the heart of Isabgul growing region, worldwide. The Company has seen uninterrupted growth since incorporation and the sales have consistently risen from Rs.85 lacs in 1991-92 to Rs.348.50 lacs in 1994-95. The Company is presently manufacturing an extensive range of Pharmaceutical Formulations for human consumption and for veteniary use. The sales therefore are divided into the two segments viz: human consumption and veterinary products. In the proposed expansion programme, the company proposes to manufacture additional tablets and injectibles for human consumption and also catering veterinary market. The company has identified the market segment for veterinary drugs as a less competitive market. Other Companies promoted by the promoter are in the business of procuring and trading in Psyllium husk. The Company procures this processed husk for its various products. Therefore, there is no conflict of interest. Also not all the raw material is procured from companies promoted by the same promoters and procurement is based on best rates available. "Gelax" is one of the main products of the company, catering to the domestic market. The Company has signed a MOU with the Indian Immunological Hyderabad (a unit of the National Dairy Development Board) for the offtake of their products. The Company has seen its exports continuously increase from Rs.5.52 lacs in 1991-92 to Rs.38.56 lacs in 1994-95. The company has received Export Orders from Companies in Kenya, and Dubai for Magnesium Silicate Compound and Isabgul Products, worth Rs.46.10 lacs. The Company is operating in an industry where there are major pharmaceutical companies - both Indian and Multinational - operating. However the company has an inherent advantage in that it is located in the heart of the Isabgul growing regions in the world with promoters well experienced in the procurement of Psyllium Husk - the major raw material for the company's products. Also it has firm marketing tie up with a major concern which has a strong brand image. 2007 E-mail ID for Investor Complaints :unjfor@sancharnet.in

Read More

Parent Organisation

Unjha Formulations Ltd.

Founded

02/09/1994

Managing Director

Mrs.Krutiben M Patel

NSE Symbol

FAQ

The current price of Unjha Formulations Ltd is

The 52-week high for Unjha Formulations Ltd is

The market capitalization of Unjha Formulations Ltd is currently This value can fluctuate based on stock price movements and changes in the number of shares outstanding.

To buy Unjha Formulations Ltd shares, you need to have a brokerage account. First, choose a reputable brokerage firm, open an account, and complete the necessary KYC procedures.

To invest in Unjha Formulations Ltd, you need a brokerage account. After opening an account and completing the KYC process, you can fund your account and use the trading platform to purchase Unjha Formulations Ltd shares.

The CEO of Unjha Formulations Ltd is Mrs.Krutiben M Patel, who has been leading the company with a vision to expand its renewable energy portfolio and drive sustainable growth.

OPEN FREE* DEMAT ACCOUNT